Peptide Therapeutics intermediate
Rimegepant - Migraine (NCT03235479)
Phase III trial of rimegepant for acute migraine. This peptide or oligopeptide is studied for its biological activity, structure-activity relationships, and ...
By Encyclopeptide Editorial | 1 min read
rimegepant-migraine-nct03235479 peptide research
Overview
Phase III trial of rimegepant for acute migraine.
Clinical Significance
This topic has important implications for peptide research and clinical applications.
References
- Encyclopeptide Database. “Rimegepant - Migraine (NCT03235479)” monograph. encyclopeptide.com.
Test Your Knowledge
Reinforce what you learned about Rimegepant - Migraine (NCT03235479) with interactive quizzes on Wikipept.
Take a Quiz on Wikipept